fashion -WSS

fashion

author：entertainment 2025-09-27 07:46:25 - browse：23489

Alnylam headquarters — Kristoffer Tripplaar/Sipa USA/AP

A group of advisers to the Food and Drug Administration voted in favor of Alnylam Pharmaceuticals’ treatment for a debilitating heart disease Wednesday, but only after a day-long debate challenging whether the drug’s modest observed effects were actually meaningful for patients.

The group of independent experts voted 9-3 that the benefits of Alnylam’s drug, called patisiran, outweighed its risks for patients with ATTR-CM, a progressive disease that leads to fatal heart failure if left untreated. The FDA, which is not required to follow the advice of advisers, is expected to make a final decision on patisiran by Oct. 8.

“It’s like a light wind blowing in favor of patisiran over placebo,” said David Cella, a neurologist at the Northwestern University Feinberg School of Medicine who voted in favor of patisiran. David Moliterno, a cardiologist at the University of Kentucky, added that “the good news in this story is that while there may be a small benefit, it doesn’t look like there’s a signal for harm.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： Will the market for weight loss drugs really reach $100 billion?

focus

WSS

It's time to retire 'poor historian' from clinicians' vocabularies

Analysis of pharma R&D ranks Novo Nordisk, J&J above their peers

Cytokinetics CEO stresses company can launch heart drug on its own

30 years of 'Listening to Prozac'

Will the market for weight loss drugs really reach $100 billion?

UnitedHealth’s Optum accused of antitrust violations in California

focus

fashion

hotspot

Affirmative action in medical school literally saved lives

Disappointing trial forces Pfizer to pivot on obesity medicine plans

Continuity nursing helped my family in our darkest PICU moments

How to pay for weight loss drugs and save Medicare

Activists slam private health insurers over coverage restrictions

Cytokinetics CEO stresses company can launch heart drug on its own

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Readout Newsletter: Nvidia, Biogen, Ionis, AstraZeneca, ChatGPT

In Memoriam: Notable people who died in 2023

Analysis of pharma R&D ranks Novo Nordisk, J&J above their peers

entertainment

Takeda, Janssen join wearable maker to measure scratching

UnitedHealth’s Optum accused of antitrust violations in California

HIV vaccine remains elusive. Immunologists keep trying new ideas

Solving academic medical centers' existential crisis

Addiction experts warn against a second 'war on drugs'

What to do when lifesaving products contribute to climate change

entertainment

focus

leisure time

entertainment